ClinicalTrials.gg
Not yet recruitingNCT07942532Updated Nov 17, 2026

Comparison of PNF and Non-Immersive Virtual Reality-Assisted PNF Exercises in Individuals With Adhesive Capsulitis

An interventional study of Conventional Physiotherapy Combined With Proprioceptive Neuromuscular Facilitation Exercises and Conventional Physiotherapy Combined With Non-Immersive Virtual Reality-Assisted Proprioceptive Neuromuscular Facilitation Exercises in Adhesive Capsulitis and Virtual Reality, sponsored by Kirsehir Ahi Evran Universitesi. Not yet recruiting. Open to participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Kirsehir Ahi Evran Universitesi · Not applicable, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
All
01

Study summary

his study aims to compare the effects of conventional physiotherapy combined with Proprioceptive Neuromuscular Facilitation (PNF) exercises and conventional physiotherapy combined with non-immersive virtual reality-assisted PNF exercises in individuals with adhesive capsulitis (frozen shoulder).

A total of 60 individuals aged 40-65 years who have been diagnosed with adhesive capsulitis will participate in this randomized controlled trial. Participants will be randomly assigned to one of two groups. The first group will receive conventional physiotherapy combined with traditional PNF exercises, while the second group will receive conventional physiotherapy combined with non-immersive virtual reality-assisted PNF exercises.

Both groups will receive treatment three times per week for six weeks, for a total of 18 sessions. Each session will last 60 minutes, including 45 minutes of conventional physiotherapy and 15 minutes of either traditional PNF exercises or virtual reality-assisted PNF exercises.

Participants will be evaluated before treatment and immediately after the six-week intervention. The assessments will examine pain intensity, pain catastrophizing, fear of movement (kinesiophobia), upper extremity function, and shoulder-specific pain and disability.

The study aims to determine whether non-immersive virtual reality-assisted PNF exercises provide additional benefits compared with traditional PNF exercises when combined with conventional physiotherapy in individuals with adhesive capsulitis.

Read the detailed description

Adhesive capsulitis is a musculoskeletal condition characterized by shoulder pain, progressive restriction of active and passive range of motion, and limitations in daily activities. Although conventional physiotherapy is commonly used to improve pain and shoulder function, additional rehabilitation approaches may provide further benefits.

Proprioceptive Neuromuscular Facilitation (PNF) is a therapeutic exercise approach involving spiral and diagonal movement patterns designed to improve neuromuscular control, coordination, and functional movement. Non-immersive virtual reality-assisted rehabilitation allows individuals to perform therapeutic movements in an interactive digital environment while receiving real-time visual feedback.

This study is designed as a two-arm, parallel-group, randomized controlled trial to investigate whether integrating non-immersive virtual reality into PNF exercises provides additional clinical and psychosocial benefits compared with traditional PNF exercises in individuals with adhesive capsulitis.

The interventions will incorporate upper extremity PNF diagonal movement patterns. In the traditional PNF group, these movements will be performed under the guidance of a physiotherapist using established PNF techniques. In the virtual reality-assisted PNF group, corresponding movement patterns will be performed through an interactive screen-based system that tracks upper extremity movements and provides real-time visual feedback.

The study will examine changes in pain intensity, pain catastrophizing, kinesiophobia, upper extremity function, and shoulder-specific pain and disability. Outcomes will be assessed using the Visual Analog Scale (VAS), Pain Catastrophizing Scale (PCS), Tampa Scale for Kinesiophobia (TSK), Disabilities of the Arm, Shoulder and Hand Questionnaire (DASH), and Shoulder Pain and Disability Index (SPADI).

By comparing these approaches, the study seeks to determine the potential contribution of non-immersive virtual reality to PNF-based rehabilitation and provide evidence regarding its clinical applicability in individuals with adhesive capsulitis.

02

Conditions studied

  • Adhesive Capsulitis
  • Virtual Reality

Browse trials for

Keywords

  • adhesive capsulitis
  • proprioceptive neuromuscular facilitation
  • virtual-reality
03

In context

Bursitis

384 studies on the registry are indexed under Bursitis; 111 are open to participants now.

This study's planned enrollment of 60 is above the median of 44 across 347 interventional studies indexed under Bursitis.

Browse Bursitis studies →

Lead sponsor

Kirsehir Ahi Evran Universitesi is the lead sponsor of 142 studies on the registry; 55 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Individuals aged 40-65 years.

Diagnosis of adhesive capsulitis confirmed by a specialist physician.

Restriction of both active and passive range of motion in the affected shoulder.

Significant limitation of shoulder external rotation compared with the contralateral side.

Ability to understand and follow verbal and visual instructions provided during the study.

Willingness to participate regularly in the six-week treatment program.

Voluntary participation in the study and provision of written .

Exclusion criteria

Exclusion Criteria:

Presence of a full-thickness rotator cuff tear, advanced glenohumeral osteoarthritis, fracture, dislocation, or in the affected shoulder.

History of previous surgery involving the affected shoulder.

Cervical radiculopathy or other neurological disorders that may affect shoulder movements.

Presence of inflammatory rheumatic diseases.

Bilateral adhesive capsulitis.

History of injection therapy in the shoulder region within the previous three months.

Participation in another shoulder rehabilitation program during the study period.

Uncontrolled cardiovascular, neurological, or systemic diseases that may interfere with exercise participation.

Severe uncorrected visual impairment that prevents participants from viewing or following the non-immersive virtual reality application.

Cognitive impairment severe enough to interfere with communication or completion of assessment questionnaires.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Conventional Physiotherapy + Proprioceptive Neuromuscular Facilitation (PNF)

    Participants in this group will receive conventional physiotherapy combined with traditional Proprioceptive Neuromuscular Facilitation (PNF) exercises. Each treatment session will last 60 minutes, consisting of 45 minutes of conventional physiotherapy and 15 minutes of therapist-guided PNF exercises. The PNF program will include upper extremity diagonal movement patterns (D1 and D2 flexion and extension). Treatment will be administered three times per week for six weeks, for a total of 18 sessions.

    Other: Conventional Physiotherapy Combined With Proprioceptive Neuromuscular Facilitation Exercises

  • Experimental
    Conventional Physiotherapy + Non-Immersive Virtual Reality-Assisted PNF

    Participants in this group will receive conventional physiotherapy combined with non-immersive virtual reality-assisted Proprioceptive Neuromuscular Facilitation (PNF) exercises. Each treatment session will last 60 minutes, consisting of 45 minutes of conventional physiotherapy and 15 minutes of virtual reality-assisted PNF exercises. The exercises will involve upper extremity diagonal movement patterns (D1 and D2 flexion and extension) performed using a screen-based interactive system that provides real-time visual feedback. Treatment will be administered three times per week for six weeks, for a total of 18 sessions.

    Other: Conventional Physiotherapy Combined With Non-Immersive Virtual Reality-Assisted Proprioceptive Neuromuscular Facilitation Exercises

Interventions

  • OtherConventional Physiotherapy Combined With Proprioceptive Neuromuscular Facilitation Exercises

    Participants will receive 45 minutes of conventional physiotherapy, including 15 minutes of superficial heat application, 15 minutes of transcutaneous electrical nerve stimulation (TENS), and 15 minutes of therapeutic exercises. Therapeutic exercises will include Codman pendulum exercises, active-assisted shoulder range of motion exercises, and stretching of the posterior shoulder capsule and pectoral muscles. Following conventional physiotherapy, participants will perform 15 minutes of therapist-guided Proprioceptive Neuromuscular Facilitation (PNF) exercises involving upper extremity D1 and D2 flexion-extension diagonal patterns. Each diagonal pattern will be performed in two sets of 10 repetitions, with 30 seconds of rest between sets. Rhythmic initiation and progressive pain-free manual resistance will be applied according to individual tolerance. Treatment will be administered three times per week for six weeks, totaling 18 sessions.

  • OtherConventional Physiotherapy Combined With Non-Immersive Virtual Reality-Assisted Proprioceptive Neuromuscular Facilitation Exercises

    Participants will receive the same 45-minute conventional physiotherapy program, including 15 minutes of superficial heat application, 15 minutes of transcutaneous electrical nerve stimulation (TENS), and 15 minutes of therapeutic exercises consisting of Codman pendulum exercises, active-assisted shoulder range of motion exercises, and stretching exercises. Following conventional physiotherapy, participants will perform 15 minutes of non-immersive virtual reality-assisted Proprioceptive Neuromuscular Facilitation (PNF) exercises. Upper extremity D1 and D2 flexion-extension diagonal movement patterns will be performed using a screen-based interactive virtual environment. A motion-tracking system will transfer upper extremity movements to virtual targets and provide real-time visual feedback regarding movement direction and completion. Treatment will be administered three times per week for six weeks, totaling 18 sessions.

06

What researchers measure

Primary outcomes

  1. Change in Shoulder Pain and Disability Index (SPADI) Total Score

    Shoulder-specific pain and disability will be assessed using the Shoulder Pain and Disability Index (SPADI). The SPADI consists of 13 items divided into two subscales: pain (5 items) and disability (8 items). Pain and disability subscale scores are calculated separately, and a total SPADI score is obtained. Scores range from 0 to 100, with higher scores indicating greater shoulder pain and functional disability. The primary outcome will be the change in the SPADI total score from baseline to the end of the six-week intervention.

    Time frame: 6 weeks

Secondary outcomes

  1. Change in Pain Intensity Assessed by the Visual Analog Scale (VAS)

    Pain intensity will be assessed using the Visual Analog Scale (VAS) under three conditions: at rest, during activity, and at night. Participants will indicate their pain intensity experienced during the previous week on three separate 10-cm horizontal lines, ranging from 0 (no pain) to 10 (unbearable pain). The distance from the starting point to the marked position will be measured in centimeters. Higher scores indicate greater pain intensity. Changes in resting, activity-related, and nighttime pain will be evaluated separately from baseline to the end of the six-week intervention.

    Time frame: 6 weeks

  2. Change in Tampa Scale for Kinesiophobia (TSK) Total Score

    Kinesiophobia will be assessed using the Tampa Scale for Kinesiophobia (TSK), which measures fear of movement associated with pain or anticipated reinjury. The scale consists of 17 items, each scored from 1 (strongly disagree) to 4 (strongly agree). After reverse-scoring four items, the total score ranges from 17 to 68, with higher scores indicating greater fear of movement. Changes in the total TSK score will be assessed from baseline to the end of the six-week intervention.

    Time frame: 6 weeks

  3. Change in Disabilities of the Arm, Shoulder and Hand (DASH) Score

    Upper extremity function will be assessed using the Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire. The DASH consists of 30 items evaluating difficulties in performing daily activities, limitations in social and occupational functioning, pain, and other upper extremity symptoms. Each item is scored from 1 to 5, and the total score is transformed to a scale ranging from 0 to 100. A score of 0 indicates no disability, while 100 indicates the greatest level of disability. Changes in the DASH score will be assessed from baseline to the end of the six-week intervention.

    Time frame: 6 week

  4. Change in Pain Catastrophizing Scale (PCS) Total Score

    Pain catastrophizing will be assessed using the Pain Catastrophizing Scale (PCS). The scale consists of 13 items divided into three subscales: rumination, magnification, and helplessness. Each item is scored from 0 (not at all) to 4 (all the time), resulting in a total score ranging from 0 to 52. Higher scores indicate greater levels of pain catastrophizing. Changes in the total PCS score will be assessed from baseline to the end of the six-week intervention.

    Time frame: 6 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for May 2027, 4 months later.

Of 219 non-industry interventional studies with no phase under Bursitis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's planned 4 months is below that.

Counting every sponsor, half of 219 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartEst.
Dec 15, 2026
Primary completionEst.
May 1, 2027
CompletionEst.
May 15, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07942532
Responsible party
Mehmet CANLI (Asst. Prof., Kirsehir Ahi Evran Universitesi) — Principal investigator
First posted
Nov 17, 2026
Start date
Dec 15, 2026 (estimated)
Primary completion
May 1, 2027 (estimated)
Completion
May 15, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Mehmet CANLI, PhD.
Contact
canlimehmet600@gmail.com
+90 5415501346
Mehmet CANLI
Contact
canlimehmet600@gmail.com
Mehmet CANLI, PhD.
principal investigator · Kirsehir Ahi Evran Universitesi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion